Clinical trial / 2024
Curcumin supplementation (500 mg/d for 24 weeks) significantly reduced hepatic fat content, weight, and glycemic markers in patients with NASFL.
In a 24-week double-blind randomized trial, 80 patients with NASFL were assigned to 500 mg/day curcumin or placebo. Compared with placebo, curcumin significantly reduced controlled attenuation parameters (-17.5 dB/m; P < 0.001), body weight (-2.6 kg; P < 0.001), BMI (-1.0 kg/m2; P = 0.032), free fatty acids, triglycerides, fasting blood glucose, HbA1c, and insulin. Curcumin also decreased the Firmicutes to Bacteroidetes ratio, increased Bacteroides abundance, elevated serum deoxycholic acid and glucagon-like peptide-1, and increased TGR5 expression.
- Study type
- Double-blind randomized controlled trial
- Who was studied
- 80 patients with nonalcoholic simple fatty liver (NASFL)
- What was measured
- Hepatic fat content (controlled attenuation parameters), body composition, gut microbiota, and bile acid metabolism
THE PAPER
Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
He Y, Chen X, Li Y, Liang Y, Hong T, Yang J, Cao Z, Mai H, Yao J, Zhang T, Wu K, Zou J, Feng D. Am J Clin Nutr, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.